[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363947-105":59,"doc-detail-363947-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","feasibility-and-safety-of-recombinant-zoster-vaccination-in-patients-undergoing-active-cancer-treatments-a-real-world-single-center-experience","Feasibility and safety of recombinant zoster vaccination in patients undergoing active cancer treatments: A real-world single-center experience","","Patients with solid tumors receiving systemic anticancer therapy face an increased risk of herpes zoster (HZ), which can delay or disrupt ongoing oncologic treatment. Although recombinant zoster vaccine (RZV) is recommended for immunocompromised adults, real-world evidence on implementation and tolerability during active cancer care remains limited. This retrospective single-center study at the G. Martino University Hospital evaluated feasibility, safety, and HZ occurrence from July 2022 to January 2025. Of 42 treated patients, 37 completed the two-dose schedule (88.1%). RZV showed favorable tolerability with mostly mild, transient injection-site pain and no severe vaccine-related adverse events or treatment delays. After a median 11.5-month follow-up, no clinically documented HZ occurred, supporting routine integration.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/feasibility-and-safety-of-recombinant-zoster-vaccination-in-patients-undergoing-active-cancer-treatments-a-real-world-single-center-experience/363947/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/feasibility-and-safety-of-recombinant-zoster-vaccination-in-patients-undergoing-active-cancer-treatments-a-real-world-single-center-experience/363947.png","ImageObject",300,407,{"name":92,"@type":93},"kopisore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What was the study objective and design?","Question",{"text":113,"@type":114},"The study retrospectively evaluated feasibility and safety of recombinant zoster vaccination for adults with solid tumors receiving or scheduled for systemic therapy in a real-world single-center setting.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How many patients received recombinant zoster vaccination and completed the two-dose schedule?",{"text":118,"@type":114},"A total of 42 patients received at least one RZV dose, and 37 patients (88.1%) completed the full two-dose schedule.",{"name":120,"@type":111,"acceptedAnswer":121},"What safety outcomes were observed during follow-up?",{"text":122,"@type":114},"Injection-site pain was the most common local adverse event. Systemic reactions such as fever and headache were mild and transient, with no severe vaccine-related adverse events and no delays in oncologic treatment.",{"name":124,"@type":111,"acceptedAnswer":125},"What herpes zoster outcomes were reported after follow-up?",{"text":126,"@type":114},"After a median follow-up of 11.5 months, no clinically documented HZ episodes were observed; the authors note this should be interpreted descriptively due to limited sample size.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},363947,1790503253,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","HUMAN VACCINES & IMMUNOTHERAPEUTICS 2026, VOL. 22, NO. 1, 2710528 [https://doi.org/10.1080/21645515.2026.2710528](https://doi.org/10.1080/21645515.2026.2710528)  \nRESEARCH ARTICLE     \nFeasibility and safety of recombinant zoster vaccination in patients undergoing active cancer treatments: A real-world single-center experience  \nGiuliana Ciappinaa,b*, Giordana Di Mauroc,d*, Enrica Toscanoe, Angela Alibrandif, Tindara Franchinae,g, Mariacarmela Santarpiae,g, Antonio Piconee, Marco Donatoe, Claudia Garipolie,g, Benedetta Raneric, Patrizia Carroccioc, Salvatore Ferrottoe, Enrica Maioranac, Paola Muscolinoc,  \nGiovanni Francesco Pellicanòh, Maria Ilenia Passalacquae, Dalila Incognitoc,d\\#, and Massimiliano Berrettae,i\\#  \naDepartment of Medical Sciences, Section of Experimental Medicine, University of Ferrara, Ferrara, Italy; bApplied Biology and Experimental Medicine, Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy; cSchool of Specialization in Medical Oncology, Department of Human Pathology “G. Barresi”, University of Messina, Messina, Italy; dTranslational Molecular Medicine and Surgery, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; e Division of Medical Oncology,“G. Martino” University Hospital, University of Messina, Messina, Italy; fUnit of Statistical and Mathematical Sciences, Department of Economics, University of Messina, Messina, Italy; gDepartment of Human Pathology of Adulthood and Childhood “G. Barresi”, University of Messina, Messina, Italy; hUnit of Infectious Diseases, Department of Clinical and Experimental Medicine, G. Martino University Hospital, University of Messina, Messina, Italy; iDepartment of Clinical and Experimental Medicine,“G. Martino” University Hospital, University of Messina, Messina, Italy  \nABSTRACT  \nPatients with solid tumors receiving systemic anticancer therapy face an increased risk of herpes zoster (HZ), a complication that can delay or disrupt ongoing oncologic treatments. Although the recombinant zoster vaccine (RZV) is recommended for immunocompromised adults, real-world data on its implementation and tolerability during active cancer treatment settings remain limited. We conducted a retrospective, singlecenter observational study at the Oncology Department of the “G. Martino” University Hospital, Messina, Italy. Between July 2022 and January 2025, the standard two-dose RZV schedule was systematically offered to adult patients with solid tumors who were receiving or scheduled to start systemic therapies. Endpoints included the operational feasibility of vaccination during oncologic care, safety, and HZ occurrence during followup. Overall, 42 patients received at least one RZV dose, and 37 (88.1%) completed the two-dose schedule. Patients were receiving different systemic anticancer treatments, mainly chemotherapy (59.5%), followed by chemo-immunotherapy and immunotherapy. RZV showed a favorable safety profile. Injection-site pain was the most frequently reported local adverse event, while systemic reactions, including fever and headache, were mild and transient. No severe vaccine-related adverse events or delays in oncologic treatment were observed. After a median follow-up of 11.5 months, no clinically documented HZ episodes occurred, although this finding should be interpreted descriptively given the limited sample size. Our experience suggests that integrating RZV into routine outpatient oncology workflows is feasible and well tolerated in patients undergoing active systemic treatments.  \nARTICLE HISTORY  \nReceived 15 May 2026 Revised 25 June 2026 Accepted 24 July 2026  \nKEYWORDS  \nHerpes zoster vaccination; cancer patients; oncologic treatments  \nIntroduction  \nCancer is a major driver of secondary immunodeficiency. Both the underlying malignancy and antineoplastic treatments, including cytotoxic chemotherapy, radiotherapy, targeted agents, immune checkpoint inhibitors (IC","cbCaitdJZ9uqx4tH","https://ap.wps.com/l/cbCaitdJZ9uqx4tH","pdf",1185019,"English","# Abstract\n# Introduction\n# Methods and Study Design\n# Results\n## Vaccination feasibility and completion\n## Safety outcomes\n## Herpes zoster occurrence during follow-up\n# Discussion and Conclusions","[{\"question\":\"What was the study objective and design?\",\"answer\":\"The study retrospectively evaluated feasibility and safety of recombinant zoster vaccination for adults with solid tumors receiving or scheduled for systemic therapy in a real-world single-center setting.\"},{\"question\":\"How many patients received recombinant zoster vaccination and completed the two-dose schedule?\",\"answer\":\"A total of 42 patients received at least one RZV dose, and 37 patients (88.1%) completed the full two-dose schedule.\"},{\"question\":\"What safety outcomes were observed during follow-up?\",\"answer\":\"Injection-site pain was the most common local adverse event. Systemic reactions such as fever and headache were mild and transient, with no severe vaccine-related adverse events and no delays in oncologic treatment.\"},{\"question\":\"What herpes zoster outcomes were reported after follow-up?\",\"answer\":\"After a median follow-up of 11.5 months, no clinically documented HZ episodes were observed; the authors note this should be interpreted descriptively due to limited sample size.\"}]","Feasibility and safety of recombinant zoster vaccination in patients undergoing active cancer treatments: A real-world single-center experience | PDF",1790154439,23,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24529dde55a0b7ac85044e54e855eab0.webp",983,1310,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72572f46c7c662fc3fe97e9175f9cef2.webp",982,1309,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c91c5dbcd6450012be0a1b097cce8130.webp",981,1308,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c5bb014fd456dbbed7214f96a0d45e1.webp",980,1306]